Product image of Mevlyq (Eribulin Mesylate) supplied by GNH India

Mevlyq

Active Ingredient:
Eribulin Mesylate
Origin:
EU

Mevlyq (Eribulin Mesylate)

Eribulin mesylate, the active ingredient in Mevlyq, is a microtubule inhibitor presented as an intravenous formulation for use in oncology patients. It is indicated for the treatment of metastatic breast cancer and for unresectable or metastatic liposarcoma.

GNH India supplies Mevlyq as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas, supporting patient access to advanced cancer therapies.

Manufacturer / TM Owner

Yes Pharmaceutical Development Services Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mevlyq (eribulin mesylate) is a microtubule‑targeting antineoplastic used in specific solid‑tumor indications.
  • Metastatic breast cancer (post‑anthracycline and taxane): improves overall survival and disease control in patients with previously treated disease.
  • Unresectable or metastatic liposarcoma (advanced disease): provides tumor shrinkage and progression‑free survival in patients with advanced disease.
  • Advanced solid tumours (clinical study): demonstrated antitumor activity in phase II trials, supporting its role in oncology research.

How It Works

  • Eribulin mesylate binds to the plus ends of microtubules, preventing further polymerisation and leading to irreversible mitotic blockade at the G2‑M transition. This disruption of the microtubule network triggers apoptotic pathways in rapidly dividing cancer cells, resulting in tumor cell death.

Side Effects

Mevlyq may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Neutropenia: decreased white blood cell count, increasing infection risk.
  • Fatigue: persistent tiredness affecting daily activities.
  • Alopecia: hair loss that may be temporary.
  • Nausea: feeling of sickness often managed with anti‑emetics.
  • Peripheral neuropathy: tingling or numbness in extremities.
  • Constipation: reduced bowel movements.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophil count, requiring urgent care.
  • Cardiac toxicity: reduced left‑ventricular function or arrhythmias.
  • Pulmonary embolism: blood clot in the lungs, presenting with sudden shortness of breath.
  • Severe infection: sepsis or opportunistic infections due to immunosuppression.
  • Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Precautions & Warnings

  • When using Mevlyq, several safety considerations should be observed.
  • Monitor blood counts: perform regular CBC to detect neutropenia.
  • Assess hepatic function: adjust use in patients with liver impairment.
  • Evaluate peripheral neuropathy: discontinue if severe symptoms develop.
  • Avoid concurrent myelosuppressive agents: increased risk of bone‑marrow suppression.
  • Pregnancy and breastfeeding: safety unknown; avoid use unless benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Eribulin mesylate can affect or be affected by other medicines.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase eribulin exposure.
  • Concurrent myelosuppressive chemotherapy (e.g., paclitaxel): heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inducers (e.g., rifampin): may reduce eribulin efficacy.
  • Anticoagulants (e.g., warfarin): monitor for bleeding due to platelet effects.
  • Live vaccines: immunosuppression may diminish vaccine effectiveness.

Frequently Asked Questions

Mevlyq, whose active ingredient is eribulin mesylate, is approved for the treatment of metastatic breast cancer that has progressed after prior chemotherapy, and for patients with unresectable or metastatic liposarcoma, a type of soft‑tissue sarcoma.

Eribulin mesylate binds to the growing ends of microtubules, blocking their elongation. This halts cell division at the G2‑M phase, leading to programmed cell death (apoptosis) of rapidly dividing tumor cells.

The dosage and infusion schedule of Mevlyq are determined by the prescribing oncologist based on the patient’s clinical condition, prior therapies, and laboratory results. No fixed regimen is provided here.

The safety of eribulin mesylate in pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To request Mevlyq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with taxanes or vinca alkaloids, eribulin has a distinct binding site that prevents microtubule growth without affecting existing filaments. Clinical trials have shown efficacy in breast cancer and liposarcoma after failure of other agents, offering an alternative mechanism for patients who have progressed on standard microtubule‑targeting chemotherapy.

Mevlyq must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution before preparation.

Mevlyq is given as an intravenous infusion, typically over a period of several minutes to an hour, depending on the prescribed protocol. The infusion is performed by qualified healthcare professionals in a clinical setting.

The most serious adverse events include febrile neutropenia, severe infections, cardiac toxicity (such as reduced left‑ventricular function), and pulmonary embolism. Patients should be monitored closely for signs of infection, cardiac symptoms, and respiratory distress.

Mevlyq is contraindicated in patients with known hypersensitivity to eribulin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled infections, or pre‑existing significant cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Eribulin Mesylate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT